LipTide® is a patented lipid and peptide-based delivery system for nucleic acids that mimics a natural virus for targeted delivery of RNA into cells. The peptide binds payload and targets specific cells while the lipid allows for efficient endosomal release into the cell. The proprietary delivery technology was developed by Nanogenics which was recently acquired by N4 Pharma.
With appealing clinical properties, the capability to deliver genetic material to almost any cell type, low toxicity, and repeat dosing, LipTide represents new promise across several therapeutic areas where there is unmet need.
As a non-viral, non-lipid delivery system, LipTide is supporting the development of a novel siRNA product for the recovery of post-surgical treatment of glaucoma and as a proprietary siRNA sequence for reducing fibrosis.
For more information about LipTide and Nanogenics, visit: https://nanogenics.co.uk/en/